Trials / Completed
CompletedNCT00375661
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Kyoto University · Academic / Other
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interferon-alfa-2b and ribavirin | Interferon, pnce per week plus daily ribavirin |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2012-03-01
- Completion
- 2013-03-01
- First posted
- 2006-09-13
- Last updated
- 2015-09-02
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00375661. Inclusion in this directory is not an endorsement.